GO:0035348 acetyl-CoA transmembrane transport

Acetyl-CoA transmembrane transport (GO:0035348) is the biological process by which acetyl-CoA, a central metabolic intermediate, is moved across cellular membranes. Acetyl-CoA is a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is produced by glycolysis, fatty acid oxidation, and amino-acid catabolism, and is consumed by the tricarboxylic acid cycle and biosynthetic pathways. Because acetyl-CoA is a charged, hydrophilic molecule, it cannot freely diffuse across lipid bilayers and requires dedicated transport proteins to reach distinct subcellular compartments. This transport step is therefore a critical node that couples central carbon metabolism to compartment-specific biosynthesis, including lipid and terpenoid production. The best-characterized mediator of acetyl-CoA transmembrane transport is the SLC33 family, specifically SLC33A1 (also known as AT-1), which localizes to the Golgi apparatus and endoplasmic reticulum and facilitates acetyl-CoA entry into these organelles. Inside the Golgi lumen, acetyl-CoA serves as the acetyl donor for O-acetylation of sialic acids, a modification that regulates cell surface interactions and signaling. In addition, acetyl-CoA transported into the endoplasmic reticulum supports protein acetylation and lipid synthesis. Disruption of this transport process has been linked to human disease, including acetyl-CoA transporter deficiency, a rare neurometabolic disorder characterized by abnormal acetylated amino acid concentrations in cerebrospinal fluid. For researchers, GO:0035348 represents a convergence point between metabolism, organelle biology, and disease. Understanding how acetyl-CoA crosses membranes is essential for interpreting metabolic flux, designing targeted therapies, and developing CRISPR-based models of transport dysfunction. This article synthesizes the current knowledge of acetyl-CoA transmembrane transport, its molecular players, its regulation, and the experimental approaches used to study it.

In simple terms, acetyl-CoA transmembrane transport is the process of carrying acetyl-CoA across a membrane. According to the QuickGO definition, it is the process in which acetyl-CoA is transported across a membrane. Acetyl-CoA is a derivative of coenzyme A in which the sulfhydryl group is acetylated; it is a metabolite derived from several pathways (e.g. glycolysis, fatty acid oxidation, amino-acid catabolism) and is further metabolized by the tricarboxylic acid cycle. It is a key intermediate in lipid and terpenoid biosynthesis. This process enables acetyl-CoA to reach membrane-enclosed compartments where it is used as a substrate for acetylation reactions and biosynthetic pathways.

Acetyl-CoA transmembrane transport is fundamentally important because it determines whether acetyl-CoA can be used in compartmentalized biosynthetic reactions. Without transport, acetyl-CoA generated in the cytosol or mitochondria cannot reach the Golgi lumen for sialic acid O-acetylation or the endoplasmic reticulum for lipid synthesis and protein acetylation. This process therefore influences cell surface properties, secretory pathway function, and membrane lipid composition. Moreover, defects in acetyl-CoA transport cause acetyl-CoA transporter deficiency, a rare disease with neurological and metabolic features. In liver disease, altered lipid droplet dynamics and autophagy are linked to acetyl-CoA availability, highlighting the broader relevance of this transport step. For researchers, GO:0035348 provides a mechanistic entry point to study metabolic compartmentalization and to develop targeted interventions.

The following genes and proteins are directly or indirectly involved in acetyl-CoA transmembrane transport, based on published literature.

Acetyl-CoA transmembrane transport is regulated by the metabolic state of the cell and by the expression levels of SLC33A1. Under conditions of high lipid demand or ER stress, SLC33A1 expression may be upregulated to increase acetyl-CoA delivery into the secretory pathway. The transport activity is also influenced by the availability of acetyl-CoA, which is determined by glycolysis, fatty acid oxidation, and amino-acid catabolism. In liver disease, autophagy modulates lipid droplets and acetyl-CoA pools, indirectly affecting transport. Additionally, in methanogens, acetyl-CoA transport is part of a regulated metabolic network responsive to substrate availability. Post-translational modifications of the transporter, such as phosphorylation, may also regulate its activity, although specific sites remain to be fully mapped.

Mutations in SLC33A1 cause acetyl-CoA transporter deficiency, a rare neurometabolic disorder characterized by abnormal concentrations of acetylated amino acids in cerebrospinal fluid. Patients present with developmental delay, spastic paraplegia, and hearing loss. The disease mechanism involves reduced acetyl-CoA transport into the Golgi and ER, leading to impaired sialic acid O-acetylation and altered protein acetylation. Studies using patient-derived cells show decreased O-acetylation of sialic acids, confirming the role of SLC33A1 in this process. This condition highlights the critical importance of acetyl-CoA transmembrane transport for normal nervous system function.

Acetyl-CoA transmembrane transport is linked to liver disease through its role in lipid droplet formation and autophagy. In hepatocytes, acetyl-CoA is required for lipid synthesis and for acetylation reactions that regulate autophagy. Disruption of transport can lead to abnormal lipid droplet accumulation and impaired autophagic flux, contributing to steatosis and liver injury. The interplay between autophagy, lipid droplets, and acetyl-CoA transport is an active area of research, with potential therapeutic implications for non-alcoholic fatty liver disease.

Defects in acetyl-CoA transport may contribute to neurodegeneration by impairing Golgi function and protein acetylation. Neurons are particularly sensitive to disruptions in acetyl-CoA metabolism because of their high energy demand and reliance on acetyl-CoA for membrane synthesis and protein modification. Abnormal acetylated amino acid profiles in CSF of patients with SLC33A1 mutations suggest a metabolic signature that could be used for diagnosis. Further research is needed to determine whether acetyl-CoA transport dysfunction plays a role in more common neurodegenerative diseases.

CRISPR-Cas9 knockout of SLC33A1 in cell lines such as HeLa or HEK293 is a powerful approach to study acetyl-CoA transmembrane transport. Knockout cells show reduced Golgi O-acetylation, which can be rescued by re-expression of wild-type SLC33A1 but not by transport-deficient mutants. This method allows causal testing of transporter function. Combined with CASD1 knockout, it can distinguish SLC33A1-dependent and -independent O-acetylation pathways.

Metabolomic analysis of cerebrospinal fluid and cell extracts can quantify acetylated amino acids, which are abnormal in acetyl-CoA transporter deficiency. Liquid chromatography-mass spectrometry (LC-MS) is used to measure acetyl-CoA levels and its downstream products. These methods provide a direct readout of transport activity and can be applied to patient samples and CRISPR models.

Immunofluorescence and lectin staining can visualize Golgi morphology and sialic acid O-acetylation in cells with SLC33A1 mutations. Antibodies specific for O-acetylated sialic acids or fluorescently labeled acetyl-CoA analogs can be used to track transport. Live-cell imaging with Golgi markers (e.g., GM130) assesses organelle integrity. These methods are useful for validating transport defects in knockout and knock-in models.

RNA sequencing of SLC33A1 knockout cells can reveal changes in lipid and glycosylation pathways. Proteomic analysis of Golgi-enriched fractions can identify proteins whose acetylation depends on transported acetyl-CoA. Integrative RNA profiling has been used in related viral infection models to identify pathogenic effectors that may impact acetyl-CoA metabolism. These approaches provide a systems-level view of the consequences of transport dysfunction.

Researchers studying acetyl-CoA transmembrane transport-related genes often need to determine whether a candidate gene is causally involved in transport, O-acetylation, or disease phenotypes. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional studies of GO:0035348 and its associated genes.

Acetyl-CoA transmembrane transport (GO:0035348) is a critical biological process that connects central metabolism to organelle-specific biosynthesis. The SLC33A1 transporter mediates the entry of acetyl-CoA into the Golgi and endoplasmic reticulum, where it supports sialic acid O-acetylation, lipid synthesis, and protein acetylation. Defects in this process cause acetyl-CoA transporter deficiency and are linked to liver disease and neurodegeneration. Continued research using CRISPR models and advanced omics will further elucidate the regulation and therapeutic potential of this transport pathway.